This study will evaluate the potential for a drug-drug interaction of PF-04937319 with ketoconazole, a potent inhibitor of the drug metabolizing enzyme CYP3A.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
10
Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
Pfizer Investigational Site
New Haven, Connecticut, United States
Cmax of PF-04937319
Time frame: Day 1 & Day 6
Tmax of PF-04937319
Time frame: Day 1 & Day 6
AUClast of PF-04937319
Time frame: Day 1 & Day 6
(as data permits) AUCinf of PF-04937319
Time frame: Day 1 & Day 6
(as data permits) t1/2 of PF-04937319
Time frame: Day 1 & Day 6
Cmax of PF-04937319 M1 metabolite
Time frame: Day 1 & Day 6
Tmax of PF-04937319 M1 metabolite
Time frame: Day 1 & Day 6
AUClast of PF-04937319 M1 metabolite
Time frame: Day 1 & Day 6
(as data permits) AUCinf of PF-04937319 M1 metabolite
Time frame: Day 1 & Day 6
(as data permits) t1/2 of PF-04937319 M1 metabolite
Time frame: Day 1 & Day 6
Urinary recovery of PF-04937319 M1 metabolite
Time frame: Day 1
(as data permits) renal clearance (CLr) of PF-04937319 M1 metabolite
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.